This article, published in the New England Journal of Medicine (NEJM), reports results from a pivotal, large-scale Phase 3 trial of RTS,S/AS01 malaria vaccine. When compared to immunization with a control vaccine, infants (aged 6 to 12 weeks at first vaccination) vaccinated with RTS,S had one-third fewer episodes of both clinical and severe malaria and had similar reactions to the injection. In this trial, RTS,S demonstrated an acceptable safety and tolerability profile. The abstract of this article is available through the NEJM by clicking on "Visit web page" below, or for free access to the full lenth article please visit malariavaccine.org and click on "Read the NEJM article."